Sitemap
- Introduction
-
Directors' Report
- Business environment
- Strategy, goals & performance measurement
- Resources, skills & capabilities
-
Financial review
- Measuring performance
- Business background & major events affecting 2008
- Results of operations - summary analysis of year to 31 December 2008
- Financial position, including cash flow & liquidity - 2008
- Restructuring & synergy costs
- Capitalisation & shareholder return
- Future prospects
- Results of operations - summary analysis of year to 31 December 2007
- Financial position, including cash flow and liquidity - 2007
- Financial risk management
- Critical accounting policies and estimates
- Other accounting information
- Geographical review
- Therapy area review
- Other businesses
- Environmental sustainability
- In the global community
- Risk
- Business organisation & corporate governance
-
Financial Statements
- Preparation of the Financial Statements & Directors' Responsibilities
- Directors' Responsibilities for, & Report on, Internal Control over Financial Reporting
- Auditors' Reports on the Financial Statements & on Internal Control over Financial Reporting
- Independent Auditors' Report to the Members of AstraZeneca PLC (Group)
- Consolidated Income Statement
- Consolidated Statement of Recognised Income & Expense
- Consolidated Balance Sheet
- Consolidated Cash Flow Statement
- Accounting Policies (Group)
-
Notes to the Financial Statements (Group)
- Notes 1-5
- 2 Finance income and expense
- 3 Taxation
- 4 Earnings per $0.25 Ordinary Share
- 5 Segment information
- Notes 6-10
- 7 Property, plant and equipment
- 8 Goodwill
- 9 Intangible assets
- 10 Other investments
- Notes 11-15
- 12 Trade and other receivables
- 13 Cash and cash equivalents
- 14 Interest bearing loans and borrowings
- 15 Financial risk management objectives and policies
- Notes 16-20
- 17 Trade and other payables
- 18 Provisions for liabilities and charges
- 19 Capital and reserves
- 20 Share capital of parent company
- Notes 21-27
- 22 Acquisitions of business operations
- 23 Post-retirement benefits
- 24 Employee costs and share option plans for employees
- 25 Commitments and contingent liabilities
- 26 Leases
- 27 Statutory and other information
- Principal Subsidiaries
- Independent Auditors' Report to the Members of AstraZeneca PLC (Company)
- Company Balance Sheet
- Accounting Policies (Company)
- Notes to the Financial Statements (Company)
- Group financial record
-
Remuneration Report
- Remuneration Committee membership & meetings
- Remuneration Committee remit & key activities during the year
- AstraZeneca's overall remuneration policy & purpose
- Components of remuneration
- Executive Directors' & the Senior Executive Team's remuneration & terms of employment
- Audit
- Directors' emoluments in 2008
- Pensions
- Transactions with Directors
- Total Shareholder Return graphs
- Director's interests in shares
- Share options
- Gains by Directors on exercise of share options
-
Additional information
-
Shareholder information
- Percentage analysis at 31 December 2008 of issued share capital
- AstraZeneca PLC
- Major shareholdings
- Related party transactions
- Options to purchase securities from registrant or subsidiaries
- Dividend payments
- Shareview
- Sharegift
- The Unclaimed Assets Register
- Results
- Documents on display
- Taxation for US residents
- UK & US income taxation of dividends
- Taxation on capital gains
- Passive foreign investment company rules
- UK inheritance tax
- UK stamp duty reserve tax & stamp duty
- Exchange controls & other limitations affecting security holders
- Exchange rates
- Definitions & interpretation
- Corporate information
- Cross-reference to Form 20-F
- Glossary
- Contact Information
-
Shareholder information
DOWNLOAD REPORT
Our report is available to download in either GLOSSARY
Abbreviations/expressions and their meanings, when used on this website
CORPORATE RESPONSIBILITY
Find out more about our commitment to responsible business
FEEDBACK
Your opinions and comments are very important to us
